Compatibility studies of nevirapine in physical mixtures with excipients for oral HAART.

Nevirapine is a hydrophobic non-nucleoside reverse transcriptase inhibitor, used in first line regimens of highly active antiretroviral therapy (HAART). The drug has more than one crystalline form, which may have implications for its behaviour during production and also for its in vivo performance. This study was aimed at exploring the suitability of thermoanalytical methods for the solid-state characterization of commercial crystalline forms of nevirapine. The drug powder was characterized by ultraviolet spectrophotometry, stereoscopy, scanning electron microscopy, wide-angle X-ray diffraction, measurements of density, flowability, solubility and intrinsic dissolution rate (IDR), differential scanning calorimetry, thermogravimetric analysis, and photostability measurements. The results showed that nevirapine has high stability and is not susceptible to degradation under light exposure. The drug showed compatibility with the excipients tested (lactose, microcrystalline cellulose, polyvinylpyrrolidone and polyvinyl acetate copolymer (PVP/PVA), and hydroxypropylmethylcellulose (HPMC)). Nevirapine has low solubility, an acid medium being the most appropriate medium for assessing the release of the drug from dosage forms. However, the data obtained from IDR testing indicate that dissolution is the critical factor for the bioavailability of this drug.

Sistemas multiparticulados: minicomprimidos / Multiparticulate systems: minitablets

Os sistemas multiparticulados contêm o fármaco subdividido em unidades funcionais, que podem ser pellets, grânulos ou minicomprimidos. Oferecem vantagens tecnológicas e biofarmacotécnicas quando comparados aos sistemas monolíticos, apresentando ainda benefícios terapêuticos para os pacientes. Por isso, têm se destacado cada vez mais dentre as novas formas farmacêuticas e sistemas de liberação de fármacos. Os minicomprimidos possuem diâmetro igual ou inferior a 2 - 3 mm e são obtidos através do processo de compressão, utilizando máquinas de comprimir convencionais adaptadas com punções múltiplos. Quanto ao aspecto tecnológico, oferecem vantagens em relação aos pellets e grânulos. O objetivo desta revisão é, portanto, abordar os principais aspectos tecnológicos envolvidos na sua obtenção, destacando suas vantagens e aplicações.

In multiparticulate systems, the drug is subdivided into functional units, which may be in the form of pellets, granules or minitablets. They have technological and biopharmacotechnical advantages over monolithic systems and also offer therapeutic benefits to patients. For these reasons, they have gained prominence among new pharmaceutical dosage forms and drug delivery systems. Minitablets are between 2 and 3 mm in diameter or smaller and are manufactured by means of the direct compression process, with a conventional tablet press adapted with multi-tip punches. In technological terms, they have advantages over both pellets and granules. The objective of this review is, therefore, to discuss the main technological features of minitablet production, highlighting their advantages and applications.

Cyclodextrins: an overview of the complexation of pharmaceutical proteins.

Cyclodextrins are oligosaccharides, specifically cyclic alpha-1,4-D-glucose oligomers, that possess a cone-like shape resulting in a hydrophobic inner cavity capable of forming complexes with several guest molecules in a hydrophilic matrix. This capability has led to an extensive investigation into cyclodextrin applications in several different substrates with the purpose of overcoming limitations, such as solubility issues, physical degradation and sensitivity to solvents, in guest substances. Researchers have recently described successful interactions between cyclodextrins and proteins, such as enzymes, peptides and amino acids. These complex biomolecules consist of potent active ingredients and are employed in several industrial biocatalyst processes. However, this group in particular tends to have limited usage in pharmaceuticals due to its natural processes of degradation and instability in unusual environments, frequently requiring accurate procedures and stabilization methods in all stages of production. In several cases, the final product still has a short shelf-life and often requires a controlled environment for storage. The formation of a cyclodextrin supramolecular complex could not only prevent such problems, but also enhance the intrinsic characteristics of guest substances, thus allowing for an expansion in their industrial production and application. This work focuses on cyclodextrin interactions with protein-like structures in order to describe their possible applications in the formulation of pharmaceutical proteins.

Desenvolvimento de formulações de comprimidos tamponados mastigáveis de didanosina com perfil de dissolução e capacidade neutralizante ácida otimizados / Development of didanosine chewable buffered tablets with optimized dissolution profile and acid neutralizing capacity.

Neste estudo buscou-se desenvolver formulações de comprimidos tamponados mastigáveis (CTM) de didanosina com eficiência de dissolução (ED%) e capacidade neutralizante ácida (CNA) otimizados, tendo como base o medicamento referência e especialidades farmacêuticas disponíveis no mercado nacional. Cinco formulações de CTM foram produzidas e avaliadas quanto a ED% e CNA, por meio de ensaio de dissolução e titulação ácido-base, respectivamente. Os resultados iniciais de CNA foram próximos aos encontrados para as especialidades farmacêuticas, aproximadamente 12 mEq HCl, porém distantes do medicamento referência (especialidade A, CNA = 17,93 mEq HCl). Já as formulações derivadas de CTM-4 conduziram à obtenção de comprimidos tamponados com CNA otimizada de aproximadamente 17,5 mEq HCl, o mesmo ocorrendo para ED%, (61,33% e 62,00%, CTM-4-2-1 e3, respectivamente). Esse resultado mostra-se próximo ao valor de 59,33% da especialidade A, quando utilizado o mesmo método de dissolução, indicando haver equivalência entre estas formulações e o medicamento referência para estes parâmetros.

The aim in this study was to develop chewable buffered tablets (CBT) of didanosine with optimized dissolution efficiency (DE) and acid-neutralizing capacity (ANC), using the reference medicine and other pharmaceutical didanosine products available in Brazil as models. Five CBT formulations were prepared and assessed for DE and ANC, through the dissolution test and acid-base titration, respectively. The initial ANC results fell short of those for the reference medicine (product A, ANC= 17.93 mEq HCl), but were close to those obtained for other pharmaceutical products (approximately 12 mEq HCl). The formulations derived from CBT-4 resulted in buffered tablets with an optimized ANC of 17.5 mEq HCl, approximately. The same was found for DE (61.33% and 62.00%, CBT-4-2-1 and CBT 3, respectively). This result proved to be close to that of product A (59.33%), when the same method was used for the dissolution test, indicating that both formulations and the reference medicine were equivalent with respect to these properties.

Inclusion complex of S(-) bupivacaine and 2-hydroxypropyl-beta-cyclodextrin: study of morphology and cytotoxicity

Local anesthetics (LA) belong to a class of pharmacological compounds that attenuate or eliminate pain by binding to the sodium channel of excitable membranes, blocking the influx of sodium ions and the propagation of the nerve impulse. S (-) bupivacaine (S(-)bvc) is a local anesthetic of amino-amide type, widely used in surgery and obstetrics for sustained peripheraland central nerve blockade. This article focuses on the characterization of an inclusion complex of S(-) bvc in2-hydroxypropyl- beta-cyclodextrin (HP-beta -CD). Differential scanning calorimetry, scanning electron microscopy andX-Ray diffraction analysis showed structural changes inthe complex. In preliminary toxicity studies, the cellviability tests revealed that the inclusion complex decreased the toxic effect (p smaller that 0.001) produced by S(-) bvc.These results suggest that the S(-) bvc:HP- beta-CD inclusion complex represents a promising agent for the treatment of regional pain.